PCE Dispertab Side Effects
Generic name: erythromycin
Note: This document contains side effect information about erythromycin. Some of the dosage forms listed on this page may not apply to the brand name PCE Dispertab.
Some side effects of PCE Dispertab may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to erythromycin: capsule, powder for suspension, suspension, tablet, tablet chewable
Other dosage forms:
Along with its needed effects, erythromycin (the active ingredient contained in PCE Dispertab) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking erythromycin:Less common
- skin rash, redness, or itching
- stomach pain (severe)
- unusual tiredness or weakness
- yellow eyes or skin–with erythromycin estolate (rare with other erythromycins)
- Pain, swelling, or redness at place of injection
- Fainting (repeated)
- irregular or slow heartbeat
- loss of hearing (temporary)
Some side effects of erythromycin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:More common
- Abdominal or stomach cramping and discomfort
- nausea or vomiting
- Sore mouth or tongue
- vaginal itching and discharge
For Healthcare Professionals
Applies to erythromycin: compounding powder, injectable powder for injection, oral capsule, oral delayed release capsule, oral delayed release tablet, oral granule for reconstitution, oral suspension, oral tablet, oral tablet chewable, oral tablet coated particles
The most common side effects associated with oral erythromycin (the active ingredient contained in PCE Dispertab) were gastrointestinal and were dose-related.
Rare (less than 0.1%): Pancreatitis, pancreatitis without biliary obstruction
Frequency not reported: Nausea, abdominal pain, diarrhea, vomiting, anorexia, infantile hypertrophic pyloric stenosis, pseudomembranous colitis, Clostridium difficile associated diarrhea (ranging from mild diarrhea to fatal colitis)
Onset of pseudomembranous colitis symptoms has been reported during or after antibacterial therapy.
Frequency not reported: QT prolongation, ventricular arrhythmias, ventricular tachycardia, torsades de pointes, arrhythmias, hypotension, polymorphous ventricular tachycardia
Postmarketing reports: Torsades de pointes
Life-threatening episodes of ventricular tachycardia associated with prolonged QT interval (torsades de pointes) have been reported following IV administration of erythromycin lactobionate.
QT prolongation has been reported both in otherwise healthy patients and in patients with a history of heart disease or who were on other potentially arrhythmogenic drugs. Most affected patients were receiving erythromycin intravenously. In a recent retrospective study of 278 consecutive patients who had received IV erythromycin lactobionate, 39% of 49 evaluable patients developed moderate to severe delay in ventricular repolarization (QTc interval greater than or equal to 500 msec) during treatment. Of the 278 patients, torsade de pointes was observed in one patient (less than 0.4%).
Arrhythmias and hypotension have been reported following IV administration.
One case of erythromycin-related polymorphous ventricular tachycardia reported in a patient treated for pneumonia was characterized by a normal QT interval.
Rare (less than 0.1%): Hepatotoxicity, fulminant hepatic necrosis, false isolated elevations of serum glutamic oxaloacetic transaminase (SGOT) enzymes
Frequency not reported: Hepatic dysfunction (including increased liver enzymes), hepatocellular and/or cholestatic hepatitis (with or without jaundice), transient elevations of liver function tests, hepatitis, abnormal liver function test results, intrahepatic cholestasis
Hepatic dysfunction (including increased liver enzymes) and hepatocellular and/or cholestatic hepatitis (with or without jaundice) have been reported with oral erythromycin.
Frequency not reported: Allergic reactions (ranging from urticaria to anaphylaxis), hypersensitivity reactions (presented as rash, eosinophilia, fever), hypersensitivity with noninfectious hepatitis
Rare (less than 0.1%): Skin rash, maculopapular rashes (generalized, pruritic)
Frequency not reported: Skin reactions (ranging from mild eruptions to erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis)
Reversible hearing loss was reported primarily in patients with renal dysfunction and in patients receiving high doses of erythromycin (the active ingredient contained in PCE Dispertab)
Several published reviews have indicated that ototoxicity was associated with erythromycin dosages greater than 4 grams per day, preexisting liver or kidney disease, and advanced age. Recovery generally occurred within two weeks.
Rare (less than 0.1%): Convulsions, reversible hearing loss, reversible ototoxicity
Frequency not reported: Exacerbation of myasthenia gravis symptoms, new onset of myasthenic syndrome
A case of hemolytic anemia has been reported in a patient with severe underlying diseases and erythromycin-associated hepatitis.
Rare (less than 0.1%): Reversible agranulocytosis
Frequency not reported: Hemolytic anemia
Frequency not reported: Interstitial nephritis
Rare (less than 0.1%): Recurrent nightmares
Slow infusion of diluted erythromycin (the active ingredient contained in PCE Dispertab) (continuously or intermittently over no less than 20 to 60 minutes) almost invariably alleviated venous irritation.
Rare (less than 0.1%): Venous irritation with IV administration
More PCE Dispertab resources
- PCE Dispertab Advanced Consumer (Micromedex) - Includes Dosage Information
- erythromycin MedFacts Consumer Leaflet (Wolters Kluwer)
- Erythromycin Monograph (AHFS DI)
- Erythromycin Professional Patient Advice (Wolters Kluwer)
- E.E.S. Granules Advanced Consumer (Micromedex) - Includes Dosage Information
- E.E.S. granules
- Ery-Tab Prescribing Information (FDA)
- Ery-Tab delayed-release tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Ery-Tab Consumer Overview
- EryPed drops MedFacts Consumer Leaflet (Wolters Kluwer)
- EryPed Prescribing Information (FDA)
- EryPed 200 Prescribing Information (FDA)
- Eryc delayed-release capsules MedFacts Consumer Leaflet (Wolters Kluwer)
- Eryc Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.